Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females

Table 7

Efficacy in less than 3-doses [68].

Endpoint	Population	Vaccine efficacy (95% CI)	Median time of follow-up
2 doses	TVC*	84% (50, 96)	4 years
1 dose	TVC*	100% (67, 100)	4 years

One-year persistence was defined as two positive tests for the same HPV type in visits 10+ months apart in women negative at enrollment for that HPV type with no intervening negatives and whose infection occurred after randomization.
TVC* means total vaccinated cohort of women who were HPV 16/18 DNA-negative at baseline regardless of serostatus and regardless of entry cytology and who had at least one follow-up datum.
Attack rate of HPV 16/18 infection in the control arm was consistently 4.5–5/100 women over the study.